Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment of a disease of the gastrointestinal tract with a TNF inhibitor

A technology for gastrointestinal diseases and gastrointestinal tract, which is applied in the field of using TNF inhibitors to treat gastrointestinal diseases, and can solve problems such as difficulties in dispensing therapeutic drugs and dispensing drugs

Pending Publication Date: 2019-11-08
BIORA THERAPEUTICS INC
View PDF68 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, dispensing drugs directly in the small intestine (e.g., cecum, ascending colon) in humans may be difficult because devices or mechanisms (e.g., special formulations) may be required to deliver a therapeutically effective amount of the drug to the desired location in the small intestine and The drug is then automatically delivered at the desired location
Dispensing therapeutics directly elsewhere in the human gastrointestinal tract may be equally difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
  • Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
  • Treatment of a disease of the gastrointestinal tract with a TNF inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[1215] Example 1 - Preclinical mouse colitis model

[1216] Experimental induction of colitis

[1217] Colitis was experimentally induced in mice by the dextran sodium sulfate (DSS) induced colitis model. This model is widely used because of its simplicity and many similarities to human ulcerative colitis. Briefly, mice were administered DSS (which is thought to be directly toxic to the colonic epithelial cells of the basal crypts) via cecal catheterization for several days until colitis was induced.

[1218] group

[1219] Depending on the agent administered, mice were assigned to one of the following seven groups:

[1220] 1. Control (no drug)

[1221] 2. Adalimumab (2.5mg / kg)

[1222] 3. Adalimumab (5mg / kg)

[1223] 4. Adalimumab (10mg / kg)

[1224] Control or agents were administered to the damaged mucosal surface of the intestine by cecal catheter administration at the dose levels described above.

[1225] Additionally, for each group, animals were divided into two...

Embodiment 2a

[1229] Example 2a - Development of a Preclinical Porcine Colitis Model

[1230] Experimental induction of colitis

[1231] Female pigs weighing approximately 35 to 45 kg were fasted for at least 24 hours at the beginning of the study before intrarectal administration of trinitrobenzenesulfonic acid (TNBS). Animals were lightly anesthetized during drug administration and endoscopy. If necessary, use a colon-cleaning enema. One animal was administered 40 ml of 100% EtOH mixed with 5 g of TNBS diluted in 10 ml of water by enema using a bulb tip catheter. The enema is deposited in the proximal portion of the descending colon just past the curvature of the transverse colon. TNBS was retained at the administration site for 12 minutes by using two Foley catheters with a 60 ml balloon placed in the middle part of the descending colon below the administration site. The second animal was treated similarly, but using a solution containing 10 grams of TNBS. Prior to TNBS administrati...

Embodiment 2

[1235] Example 2b - Pharmacokinetics / pharmacodynamics and bioavailability of adalimumab following topical administration

[1236] group

[1237] Sixteen (16) pigs (approximately 35 to 45 kg at the start of the study) were assigned to one of five groups:

[1238] 1. Vehicle control: (3.2mL normal saline); in rectum; (n=2)

[1239] 2. Treatment control: Adalimumab (40 mg in 3.2 mL saline); subcutaneous; (n=2)

[1240] 3. Adalimumab (low): Adalimumab (40 mg in 3.2 mL saline); intrarectally; (n=4)

[1241] 4. Adalimumab (medium): Adalimumab (80 mg in 3.2 mL saline); intrarectally; (n=4)

[1242] 5. Adalimumab (high): Adalimumab (160 mg in 3.2 mL saline); intrarectally; (n=4)

[1243] On day 0, the test articles were administered intrarectally or subcutaneously to the damaged mucosal surface of the intestine at the above dose levels and volumes by a veterinarian.

[1244] Clinical Observations and Body Weight

[1245] Clinical observations were performed at least once a day. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TNF inhibitor.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of the following U.S. provisional applications: 62 / 434,363 filed December 14, 2016, 62 / 479,118 filed March 30, 2017, 62 / 545,240 filed August 14, 2017, and 62 / 583,768 filed November 9, 2017. These disclosures of the earlier applications are considered part of the disclosure of the present application (and are hereby incorporated by reference in their entirety). technical field [0003] The disclosure features methods and compositions for treating gastrointestinal disorders with TNF inhibitors. Background technique [0004] Tumor necrosis factor alpha (also known as TNF-alpha, TNF-alpha, cachexin, and cachectin) is a cell-signaling pro-inflammatory cytokine primarily produced by activated macrophages and T lymphocytes, but it can also be produced by other cells Types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils and neurons are produced. TNF-α is localized...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61B5/00A61M31/00C07K16/24
CPCA61B5/6861A61B5/0075A61B5/01A61B5/024A61B5/0538A61B5/06A61B5/062A61B5/066A61B5/073A61B5/14539A61B5/14546A61B5/1459A61B5/42A61B5/4839A61M31/002C07K16/241C07K16/244A61K2039/542A61P1/00A61P1/04A61B2010/0061A61K9/0065A61K38/191A61M2205/3306A61M2205/8231A61M2205/8275A61M2205/3523A61M2210/1053A61M2210/106A61B5/063A61K9/0053A61J1/03A61B1/041A61B5/07A61B6/425A61B6/4057
Inventor M.L.琼斯S.辛哈C.L.瓦尔H.斯特利
Owner BIORA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com